Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial

20250 citationsJournal Article

Authors

Monika Graeser · Witten/Herdecke University

Oleg Gluz · University of Cologne

Peter Schmid · Queen Mary University of London

Katarzyna Jóźwiak · Medizinische Hochschule Brandenburg Theodor Fontane

Christine zu Eulenburg · Universität Hamburg

Friedrich Feuerhake · University of Freiburg

Valery Volk

Abstract

Our multiomic analysis uncovered mechanisms of tumor response to immunotherapy combined with dual HER2 blockade. These results could inform the design of larger trials investigating chemotherapy-free regimens in selected patients with HER2+ early breast cancer.

Topics & Keywords

HER2/EGFR in Cancer Research Cancer Immunotherapy and Biomarkers Breast Cancer Treatment Studies

Publication Details

Published in: Clinical Cancer Research

Volume 32, Issue 1, pp. 214-223

DOI: 10.1158/1078-0432.ccr-25-1923

Field-Weighted Citation Impact: 0.00

Command Palette

Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial

Authors

Abstract

Topics & Keywords

Publication Details